Despite a reduction in mortality from cardiovascular diseases over the last few decades, the mortality caused by these diseases in the UK is among the highest in the world. Cardiovascular diseases constitute the single most common cause of mortality in most Western populations. 1 Elevated blood cholesterol concentrations, high blood pressure and cigarette smoking explain much of the differences in cardiovascular disease rates within and between populations. 2 In addition to the established importance of lowering blood pressure, recent clinical trials have clearly demonstrated that lowering blood cholesterol concentration is associated with highly signi®cant reductions in coronary heart disease (CHD), stroke and`all-cause' mortality. 3±5 Research interest has expanded into the study of emerging risk factors for cardiovascular disease, including homocysteine. Over the last decade, evidence has accumulated that elevated plasma homocysteine concentrations are associated with an increased risk of atherosclerotic and thrombo-embolic events. 6±8 Plasma concentrations of homocysteine re¯ect genetic and environmental factors, including diet. 9, 10 Vitamin supplementation with folic acid and vitamin B 12 achieves substantial reductions in blood homocysteine concentrations. 11 Several large-scale trials are currently underway to assess whether vitamin supplementation to lower homocysteine concentrations can reduce the risk of vascular disease. 12 This review describes the metabolism of homocysteine, including its vitamin dependence, genetic and environmental determinants of homocysteine, the relevance of homocysteine as a risk factor for cardiovascular disease and practical issues in the assessment of homocysteine status.
METABOLISM
Homocysteine is a sulphur amino acid derived from methionine, following the loss of a methyl group. The formulae of these and related metabolites are shown in Fig. 1 . Homocysteine lies at a branch point in one-carbon metabolism between two metabolic pathways (remethylation and trans-sulphuration)in all cells (see Fig. 2 ). In the remethylation pathway, homocysteine accepts a methyl group from the methyl-tetrahydrofolate to form methionine. The remethylation reaction, catalysed by methionine synthase (MS), requires vitamin B 12 as a cofactor and methyltetrahydrofolate as substrate. Methylene-tetrahydrofolate reductase (MTHFR) plays an important role in remethylation, by supplying methyl groups as methyl-tetrahydrofolate for homocysteine remethylation. An alternative remethylation pathway utilizing betaine as methyl donor is con®ned to the liver. Much of the methionine is activated to form S-adenosylmethionine (SAM), which is the chief donor of methyl groups for methyl transferases involved in the synthesis of DNA, proteins and phospholipids. The loss of the methyl group from SAM results in the production of S-adenosylhomocysteine (SAH), which is in turn hydrolysed to form homocysteine.
In the trans-sulphuration pathway, homocysteine condenses with serine to form cystathionine in an irreversible reaction catalysed by vitamin B 6 -dependent cystathionine-b-synthase (CS). Under normal circumstances the¯ow of methionine to cystathionine accounts for half of all methionine metabolism. The remaining half of total body homocysteine is remethylated by methyl groups derived in equal amounts from methyltetrahydrofolate or betaine. 13 The intracellular levels of homocysteine are highly regulated, and any increased production is met by export from cells. Thus, blood levels of homocysteine re¯ect intracellular concentrations of homocysteine and the homeostatic balance of the enzymes involved in methionine metabolism to ensure a supply of methyl groups for essential reactions in all cells.
GENETIC INFLUENCES
Homocystinuria and severe hyperhomocysteinaemia (> 100 mmol/L) are usually caused by rare inborn errors of metabolism. 14 Cystathionine-bsynthase de®ciency is the most common genetic cause of severe hyperhomocysteinaemia, with an estimated frequency of 1 per 300 000 live births. Approximately 1% of the general population is heterozygous for CS de®ciency and these have homocysteine levels in the range of 20±40 mmol/ L. 15 Heterozygotes for CS de®ciency have higher risks of occlusive vascular disease. 14 A thermolabile variant of MTHFR due to a C?T substitution in the gene (C677T) encoding this enzyme is a much more frequent mutation, affecting 5±15% of the population. 16 The C677T mutation for MTHFR causes a single amino acid substitution which results in altered binding of folate. 16 Individuals who have the TT mutation have about 25% higher homocysteine levels than do individuals with the CC variant, depending on their folate status. Individuals with this mutation are particularly sensitive to folate and ribo¯avin de®ciency. 17, 18 Despite the association of MTHFR mutation with elevated homocysteine levels, the evidence relating this mutation with cardiovascular disease is con¯icting. 19, 20 Some of the discrepant results between individual studies may relate to differences in dietary intake of folate and ribo¯avin levels in these populations, whereby the effects of this mutation on cardiovascular risk are chie¯y manifest in the presence of folate and ribo¯avin de®ciency. 17, 18 Other recently discovered genetic variants include defects of methionine synthase 21 and methionine synthase reductase, 22 but these have less signi®cant effects on homocysteine levels than MTHFR.
DIETARY INFLUENCES
Dietary intake of folate, vitamin B 12 and vitamin B 6 are the chief nutritional determinants of blood homocysteine concentrations, with folate being the predominant vitamin. 9,10 Observational studies show a linear relationship of increasing blood folate levels and a decreasing homocysteine concentration with increasing intake of dietary folate. The Framingham study demonstrated that those in the top decile of dietary folate intake had homocysteine levels that were about 5 mmol/L lower than did those in the bottom decile. 9 More reliable evidence for the effects of individual vitamins on blood homocysteine levels comes from the clinical trials comparing the effects of such vitamins on homocysteine levels.
Combined analysis of the effects of these vitamin trials suggest that folic acid in a dose ranging from 0´5 to 5 mg daily was associated with reductions in homocysteine levels of about 25%. 11 The addition of vitamin B 12 to folic acid was associated with further reductions in homocysteine levels of about 7%. Hence, a multivitamin combination of folic acid and vitamin B 12 was associated with reductions in homocysteine levels of about one-third (i.e. from a mean concentration of 12 to 8 mmol/L). Vitamin B 6 supplementation did not appear to affect basal homocysteine levels, but was associated with a reduction in homocysteine levels after methionine loading. 11
ASSESSMENT OF HOMOCYSTEINE STATUS
In plasma, 70% of homocysteine is bound to albumin, the remaining 30% forming disulphides with other thiols, and only 1% circulates in a free form. The sum of these homocysteine forms is referred to as total homocysteine or homocyst(e)ine. Assays of`total homocysteine' 23, 24 convert these multiple unstable thiols to a reduced form which can be measured directly or, after derivatization, by high-performance liquid chromatography [HPLC; coef®cient of variation (CV)55%] or gas chromatography± mass spectrometry (GCMS; CV 4%).
The introduction of immunoassays for homocysteine determination now affords a highly practical and cost-effective method for homocysteine determination. 25±27 AXIS-Shield (Oslo, Norway) has developed two variants of immunoassay for homocysteine determination, one a¯uorescence polarization immunoassay (FPIA) which runs on the IMx system (Abbott Laboratories, Chicago, USA), and the other an enzyme immunoassay (EIA) that can be carried out on a microtitre plate. 27 The intra-laboratory imprecision is less than 5% for the FPIA method and less than 9% for the EIA method using automated pipetting. 27 Figure 3 shows a comparison of the performance of the FPIA and EIA immunoassays with those carried out by GCMS as part of a multicentre European Demonstration project. 27 The Demonstration project showed that the immunoassays for homocysteine determination could safely be used in place of assays carried out by HPLC or GCMS. A comprehensive review of the performance of the different homocysteine assays, including sample volume, analytical imprecision, throughput and quality control schemes, has recently been published. 28 Meticulous attention to detail in sample handling is important for accurate homocysteine determination. Plasma concentrations of homocysteine rise rapidly unless plasma is separated from red cells immediately or kept chilled at 4°C. Homocysteine levels in unseparated whole blood stored at room temperature (in the UK approximately 23°C) increase by about 10% per hour, and higher ambient temperatures result in a greater increase. After prompt separation of red cells, homocysteine concentrations in plasma remain stable for several days at room temperature or 4°C and for several years at 720°C. Plasma samples can therefore be sent to laboratories by ®rst-class post for analysis. EDTA is a convenient anticoagulent (as is lithium heparin); serum is less desirable because the inevitable separation delay leads to elevations in homocysteine concentration. An alternative to prompt separation is the stabilization of blood homocysteine by 3-deaza-adenosine 29 or¯uoride (the amount of¯uoride in a¯uoride± oxalate tube is quite adequate).
Plasma homocysteine concentration is higher in men than in women and increases with age, renal impairment and following a meal containing a signi®cant amount of methionine and certain drugs (see Table 1 ). The mean homocysteine concentration also varies according to an individual's dietary intake of folate and other vitamins. Assessment of homocysteine status therefore requires age-and sex-related reference ranges. But for most practical purposes, the normal middle-aged adult plasma concentrations of total homocysteine lie between 8 and 15 mmol/L. For individuals aged 65 years or greater, a plasma homocysteine concentration of 20 mmol/L or greater would be considered abnormal. The American Heart Association have arbitrarily de®ned hyperhomocysteinaemia as being divided into moderate, intermediate and severe, referring to concentrations 515±30, 30± 100 and 4100 mmol/L, respectively. 30 Homocysteine concentration within individuals remains relatively stable at least for a year, 31 within-person standard deviation in homocysteine concentrations is 1 mmol/L within one year. 10 A single blood sample, which need not be from a fasting patient, is the most widely used investigation to assess homocysteine status, and in practice a light breakfast has little in¯uence on it. 7 Oral methionine loading (0´1 g/kg of L-methionine) leads to about a three-fold increase in plasma homocysteine concentration at 6 h and detects latent disorders of remethylation and trans-sulphuration. It was originally used to identify carriers for homocystinuria, but more recently has been used to identify latent hyperhomocysteinaemia regardless of the aetiology. While it has been suggested that some people with a normal fasting plasma homocysteine may have hyperhomocysteinaemia revealed by the methionine-loading test, the relevance of this to clinical outcomes is uncertain. 32±35 The actual cut-off points for an abnormal methionine loading test have been de®ned as being 42 standard deviations (SD) above the mean level in controls (i.e. 435± 40 mmol/L, depending on age). Folate concentration and MTHFR TT genotype in¯uence the post-methionine increase in homocysteine, as does gender, 33 women showing greater increases than men. However, homocysteine concentration after methionine loading is highly correlated with random basal homocysteine concentration, measurement of which is easier to perform, cheaper and less unpleasant for the patient. Also, there is substantial uncertainty about the reproducibility of homocysteine concentration measurement in response to methionine loading, which may explain the con¯icting results about the predictive value of methionine load-induced homocysteine concentration as a risk factor for cardiovascular disease, independent of random or`basal' homocysteine concentration. Hence, methionine loading tests should probably be restricted to research purposes.
EVIDENCE RELATING HYPERHOMOCYSTEINAEMIA TO VASCULAR DISEASE
There is now evidence from a large number of epidemiological studies conducted in different settings of a positive association between blood concentration of homocysteine and risk of cardiovascular disease. 6±8 Thus, patients with heart disease, 36±42 stroke, 43, 44 peripheral vascular disease 45±47 and thromboembolic disease have higher blood concentrations of homocysteine than do age-matched individuals who are disease-free. Throughout the typical range of plasma homocysteine concentrations encountered in Western countries (8±15 mmol/L), lower concentrations are associated with lower risks of vascular disease. As stated above, plasma concentrations of homocysteine increase with age and are greater in men than in women and greater in current smokers than in non-smokers. 7 Plasma concentrations of homocysteine are positively correlated with levels of systolic blood pressure, creatinine and with total and LDL-cholesterol, and inversely correlated with HDL-cholesterol and current alcohol consumption. 7 Despite this correlation of plasma homocysteine with other cardiovascular risk factors, the associations of homocysteine with vascular risk appear to be independent of other cardiovascular risk factors. 8 Prospective studies show that differences in concentrations of plasma homocysteine precede the onset of disease, which would appear to argue against differences in homocysteine concentrations being simply a marker of sub-clinical disease. 36±42 An overview of published studies 8 shows that the odds ratio for coronary disease associated with a 5 mmol/L increase in homocysteine concentration in prospective studies was 1´3 [95% con®dence interval (CI): 1´1 to 1´5], which is less marked than that observed in retrospective studies with population controls, in which the odds ratio was 1´6 (95% CI: 1´4 to 1´7), or in retrospective studies with volunteer controls, in which the odds ratio was 1´9 (95% CI: 1´6 to 2´3). Some of the discrepant results of prospective studies may relate to differences in the mean time to events in such studies. There is a trend whereby the strength of association of plasma homocysteine concentration with cardiovascular disease appears to attenuate at longer intervals of follow-up in such studies. These issues are currently being addressed in a meta-analysis of individual patient data from all the available observational studies of homocysteine and cardiovascular disease.
EVIDENCE OF CLINICAL BENEFIT FROM VITAMIN SUPPLEMENTATION
Observational studies cannot exclude the in¯uence of confounding factors, including dietary factors, which may explain the modest relative differences observed. 12 This trial is one of seven large-scale trials that will provide randomized evidence for the effects of homocysteine-lowering therapy in 40 000 patients with prior heart disease. 12 The VISP (Vitamin Intervention for Stroke Prevention) and VITATOPS (Vitamins to Prevent Stroke) trials will provide randomized evidence for the effects of homocysteine-lowering therapy in patients with prior stroke. 12 The VITRO (Vitamins and Thrombosis) trial will assess the effects of homocysteine-lowering therapy for thromboprophylaxis in patients with previous venous thrombosis and the FACIT (Folic Acid and Carotid Intima-media Thickness) trial will assess the effects of homocysteine lowering on carotid artery intima±media wall thickness in healthy elderly patients.
The results of these large-scale trials are required to establish whether the associations of homocysteine with vascular risk are causal or not. Consequently, de®nitive recommendations about widespread screening of patients for elevated homocysteine concentrations cannot be justi®ed until it is clearly demonstrated that use of vitamin supplements to lower homocysteine concentration is associated with a reduction in cardiovascular risk. However, individual clinicians may wish to measure homocysteine concentration as a marker of risk in patients presenting with coronary heart disease at an early age or with a paucity of other known risk factors. Individuals with prior cardiovascular disease and moderately elevated homocysteine concentrations should have careful assessment and appropriate treatment of established risk factors such as smoking, elevated blood pressure and elevated blood cholesterol concentrations.
